BIO 2015 Dispatches: Asset Swaps Won't Replace Mega-mergers
This article was originally published in The Pink Sheet Daily
Executive Summary
Business development executives from AstraZeneca, Novartis and Almirall discussed the benefits of assets swaps and if they think mega-mergers are an outdated trend.
You may also be interested in...
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.